Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Beta Bionics, Inc. BBNX

3 fiscal years on record · USD · FY2025 reported · SEC filings only
$100.3M
▲ 53.9% YoY
$-73.2M
$-56.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of closed-loop algorithm-based solutions for insulin-requiring people with diabetes. The company markets and distributes the iLet in the United States through a direct commercial organization that includes sales, clinical and customer support teams. It manufactures and assembles the iLet and related insulin cartridges at its facility in Irvine, California, which serves as its primary manufacturing and distribution center. As of December 31, 2025, the installed base of the iLet had grown to 35,011 units. As of December 31, 2025, the company had 420 full-time employees and three part-time employees.

Written from the business description in BETA BIONICS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 100.3M
Revenue, FY2025 · full 3-year series below
Revenue $M Net income $M
FY2025 · Revenue 100.3 · Net income -73.2
50M100M-30M-60M
202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−73 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -71.5% · Net -73.0%
-100%-200%-300%
202320242025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -34%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -56.2
-20M-40M
202320242025

Total assetsUSD 328.7M
EquityUSD 287.6M
CashUSD 31.6M
Current ratio8.66×

Equity funds 87% of total assets.

The 3-year record

3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BBNX, 3-year financial record
Metric 202520242023
Revenue $B0.10.10.0
Operating income $B−0.1−0.0−0.0
EBITDA $B−0.1−0.0−0.0
Income tax $B0.00.0◌
Net income $B−0.1−0.1−0.0
Free cash flow $B−0.1−0.1−0.0
EPS, diluted $−1.81−8.60−8.31
Dividend / sh $◌◌◌
Payout % — not applicable: no dividend———
ROE % — not applicable: negative equity———
Shares out B0.040.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of the 3 fiscal years we could check. 32 checks were skipped: the balance sheet is not tagged before 2023. 16 checks were skipped: EPS is not tagged before 2023. 16 checks were skipped: revenue is not tagged before 2023.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2023

Share this section

Download image